Outpatient management of asthma in adults: A snapshot of the 2020 GINA report

Kommaraju, Kamya; Latifi, Mani

doi:10.3949/ccjm.88a.20167

Cited by 5 publications

(4 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When SABA is administered, low-dose ICS should also be utilized. 1,5,7,8 Thus, sufficient knowledge and awareness among physicians and other healthcare providers are required to manage asthma and limit its exacerbation, directly influencing lower death rates and economic costs. 2 This study aimed to ascertain the knowledge and how healthcare professionals in Jordan manage adult asthmatic patients according to the global medical resources, focusing on adherence to the GINA 2019-2022 recommendations.…”

Section: Introductionmentioning

confidence: 99%

“…The committee issues new recommendations practically almost every year while meeting every two years with the American Thoracic Society (ATS) and the European Respiratory Society (ERS) to examine the most recent discoveries in asthma research. 1 , 5 By collaborating with medical experts and public health officials worldwide, GINA seeks to raise awareness of asthma, its symptoms, causes, and means of prevention and management. The most significant shift in asthma management in the past 30 years was made when GINA issued its recent guidelines in 2019 that updated how mild asthma is treated.…”

Section: Introductionmentioning

confidence: 99%

“…Therefore, to reduce this risk, all asthmatic individuals should get combination treatment with long-acting beta-agonists (LABA) and inhaled corticosteroids (ICS) when needed for mild asthma or routinely every day for moderate or severe asthma. 5 , 7 Moreover, low-dose budesonide-formoterol or beclomethasone-formoterol is recommended as a first-line treatment as a reliever and controller medication. When SABA is administered, low-dose ICS should also be utilized.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Knowledge and Practice of Healthcare Professionals in the Medical Care of Asthma Adult Patients in Jordan with a Particular Reference to Adherence to GINA Recommendations

Al-hamaden,

Abed,

Khader

et al. 2024

JMDH

View full text Add to dashboard Cite

This study aimed to evaluate Jordanian healthcare professionals' knowledge, skills, and experience in dealing with and treating adult asthmatic patients and assess healthcare professionals' compliance with the Global Initiative for Asthma (GINA) guideline recommendations for asthma treatment and management in Jordan. Patients and Methods: A cross-sectional survey was conducted in Jordan between May and June 2023. This study included physicians, pharmacists, and nurses working in clinical settings and directly interacting with asthma patients in Jordan's private and governmental healthcare facilities who were eligible to participate in this research. Three primary sections of an online survey were constructed using Google Forms and included demographic data, a diagnosis and management of the illness, and a list of worldwide medical references for asthma. Results: A total of 300 healthcare professionals, including pharmacists (103), nurses (87), Doctor of Pharmacy (28), and physicians (82), took part in this research. The survey respondents' general knowledge of the nature and symptoms of asthma is quite high, exceeding 84% and 86%, respectively. The survey also showed a high degree of awareness of asthma diagnosis. It was also revealed that around one-quarter of participants consistently reported the severity of asthma. The most frequent factor influencing the decision to take controller or maintenance medicines is symptom severity (reported from 86% of participants). The GINA guidelines were selected as the asthma information source by almost half of the participants. Finally, 47% of participants were aware of the GINA's 2019 adjustments of the recommendations. Conclusion:This study showed that Jordanian healthcare professionals understand the nature, symptoms, and diagnoses of asthma disease. However, many of the survey participants lack adherence, awareness, and understanding of the GINA recommendations about asthma management. More research is required to assess the adherence to the evidence-based recommendations and evaluate the impact of training courses.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Knowledge and Practice of Healthcare Professionals in the Medical Care of Asthma Adult Patients in Jordan with a Particular Reference to Adherence to GINA Recommendations

Al-hamaden,

Abed,

Khader

et al. 2024

JMDH

View full text Add to dashboard Cite

show abstract

“…The pulmonary community has spent a great deal of time and effort over the past 60 years focused on components of this spectrum of illnesses ( 1 ). Much of this focus has been on precise definitions of what makes up obstruction ( 2 ), restriction ( 3 ), bronchitis ( 4 ), asthma ( 5 ), emphysema ( 6 ), and the various degrees of overlap between these components ( 7 ).…”

mentioning

confidence: 99%

Insights into the Spectrum of Chronic Lower Respiratory Disease: Low Lung Function Is Still Bad

Mannino

2021

Am J Respir Crit Care Med

View full text Add to dashboard Cite

The Benefit of Benralizumab Monoclonal Antibody Treatment for Severe Eosinophilic Asthma in a Case Series (Pulmonology Clinic Târgu Mureș, Romania)

László¹,

Sárközy

Man³

et al. 2021

Journal of Interdisciplinary Medicine

View full text Add to dashboard Cite

Background: Monoclonal antibody therapy is currently an additional treatment option to reduce exacerbations and improve symptom control in patients with severe eosinophilic asthma (SEA) that is uncontrolled despite treatment with high-dose inhaled corticosteroids and long-acting beta-2 agonists. Benralizumab, a monoclonal antibody that binds to the interleukin-5 receptor (IL-5), significantly reduces symptoms and annual exacerbations, as well as the use of systemic corticosteroids in patients with SEA. However, few studies are available on the effectiveness of this biological treatment in real life. The aim of this case series was to evaluate the efficacy of benralizumab by analyzing changes in clinical parameters and blood eosinophils in patients with SEA. Methods: We analyzed four patients with SEA who started treatment with benralizumab. The history of symptoms and exacerbations, eosinophil counts, data regarding the oral corticosteroid dose, need for rescue treatment, spirometry measurements and asthma control questionnaires (ACT) regarding the level of asthma control were recorded. A positive response to treatment was defined by a significant reduction in eosinophil counts, increased ACT scores, and lower rates of exacerbations. Results and conclusions: Benralizumab monoclonal antibody was effective in all four patients. This was shown by a reduction in exacerbation rates, symptom severity, and lower dose of oral corticosteroids and rescue medication. This novel treatment was well tolerated by the analyzed patients, thus indicating that benralizumab is an attractive choice for patients due to eosinophilic count reduction as well as the less frequent dosing schedule. However, further studies are required, on larger populations.

show abstract

Outpatient management of asthma in adults: A snapshot of the 2020 GINA report

Cited by 5 publications

References 8 publications

Knowledge and Practice of Healthcare Professionals in the Medical Care of Asthma Adult Patients in Jordan with a Particular Reference to Adherence to GINA Recommendations

Knowledge and Practice of Healthcare Professionals in the Medical Care of Asthma Adult Patients in Jordan with a Particular Reference to Adherence to GINA Recommendations

Insights into the Spectrum of Chronic Lower Respiratory Disease: Low Lung Function Is Still Bad

The Benefit of Benralizumab Monoclonal Antibody Treatment for Severe Eosinophilic Asthma in a Case Series (Pulmonology Clinic Târgu Mureș, Romania)

Contact Info

Product

Resources

About